Ülkü Yılmaz, Pinar Akin Kabalak, Funda Demirag, Derya Kizilgöz

Application of endobronchial ultrasound-guidedtransbronchial needle aspiration for re-biopsy in lungcancer

Aim: The initial mutation status of non-small cell lung cancer (NSCLC) is important for guiding treatment. However, re-biopsy is needed to determine the new mutation status in patients receiving targeted therapy or who develop resistance during first-line therapy. Endobronchial ultrasound (EBUS) is an important tool to obtain adequate tissue for molecular analyses. Materials and Methods: We used a clinical database of 349 patients who were previously included in a multi-center study. Adequacy of tissue collected, new molecular profile, and treatment regimens were evaluated.Results: A total of 50 patients (median age of 60 ± 9 years) received biopsy by EBUS. The success rate was 36% (n = 18), and repeat re-biopsy was performed for patients with anthracosis (n = 32). In 18 patients, only one lymph node station was sampled. Initial histopathology was adenocarcinoma in 28 patients, squamous cell carcinoma (SCC) in 18 patients, and not otherwise specified (NOS) in four patients. No correlation was found between initial treatment type and success rate of the procedure (p = 0.101). After re-biopsy in six patients (five of whom had newly detected mutations), targetable mutations were detected for T790M (n = 2), EGFRexon 19 (n = 1), c-Met (n = 1), and EGFR-21 (n = 2).Conclusion: : In cases of resistance to treatment, re-biopsy should be performed to detect different gene amplifications. Re-biopsy with EBUS is an effective method for an appropriate progressive lesion.

PDF

___

1. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014;25:1475-84.
2. Ko R, Kenmotsu H, Serizawa M, et al. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC Cancer 2016; 16: 864.
3. Yang JC, Ahn MJ, Kim DW et al. Osimertinib in pretreated T790M-positive advanced non-smallcell lung cancer: AURA study phase II extension component. J Clin Oncol 2017;35:1288-96.
4. Chouaid C, Dujon C, Do P, et al. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a realworld setting (GFPC study 12-01). Lung Cancer 2014;86:170-3.
5. Nosaki K, Inamasu E, Shimamatsu S, et al. Re-biopsy in advanced non-small cell lung cancer patients after the development of 3rd generation EGFR-TKI and new targeted therapies. J Clin Oncol 2015;33:19081.
6. Hata A, Katakami N, Nanjo S, et al. Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo 2017; 31:475-9.
7. Ece D, Keser SH, Cağlayan B, et al. Endobronchial Ultrasound-Guided Transbronchial Fine Needle Aspiration: Determinants of Adequacy. Turk Gogus Kalp Damar Cerrahisi Derg 2018 26:123-31.
8. Kim J, Kang HJ, Moon SH, et al. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Re-biopsy in Previously Treated Lung Cancer. Cancer Res Treat 2019;51:1488-99.
9. Izumo T, Matsumoto Y, Chavez C, et al. Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment. BMC Pulm Med 2016;16:106.
10. Demirci NY, Alici IO, Yilmaz A, et al. Risk factors and maximum standardized uptake values within lymph nodes of anthracosis diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Turk J Med Sci 2015;45:984-90.
11. Kirchner J, Broll M, Müller P, et al. CT differentiation of enlarged mediastinal lymph node due to anthracosis from metastatic lymphadenopathy: a comparative study proven by endobronchial US-guided transbronchial needle aspiration. Diagn Interv Radiol 2015;21:128-33.
12. Ho HL, Kao HL, Yeh YC, et al. The importance of EGFR mutation testing in squamous cell carcinoma or nonsmall cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. Diagn Pathol 2019;14:59.